Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials by unknown
ORIGINAL RESEARCH
Assessing Short-term Deterioration in Maintenance-
naı¨ve Patients with COPD Receiving Umeclidinium/
Vilanterol and Tiotropium: A Pooled Analysis of Three
Randomized Trials
M. Reza Maleki-Yazdi . Dave Singh . Antonio Anzueto . Lee Tombs .
William A. Fahy . Ian Naya
Received: August 25, 2016 / Published online: October 28, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Dual bronchodilator therapy is
reserved as a second-line treatment in patients
with chronic obstructive pulmonary disease
(COPD) and provides benefits in lung function
and health status versus monotherapy. The aim
of this study was to determine whether early
initiation of a dual bronchodilator versus
monotherapy reduced the risk of deterioration
in COPD.
Methods: This post hoc pooled analysis
investigated the efficacy and safety of
umeclidinium/vilanterol (UMEC/VI) 62.5/
25 mcg/day compared with tiotropium (TIO)
18 mcg/day in a maintenance-naı¨ve (MN)
subgroup of patients relative to the
intent-to-treat (ITT) population from three
6-month active comparator studies (n = 1747).
Other treatment arms (UMEC/VI 125/25, VI 25
and UMEC 125) comprised 850 patients in total
but were not included in this analysis. The
primary endpoint was trough forced expiratory
volume in 1 s (FEV1). St George’s Respiratory
Questionnaire (SGRQ) score, rescue medication
use, and a novel composite endpoint of
short-term clinically important deterioration
(CID; C100 ml decrease in trough FEV1,
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C4-unit increase in SGRQ score, or a COPD
exacerbation) were also assessed.
Results: UMEC/VI improved trough FEV1
versus TIO at day 169 [least squares mean
(95% confidence interval): MN: 146 ml
(102–189) and ITT: 95 ml (71–118); both
P\0.001]. Both UMEC/VI and TIO improved
SGRQ and rescue use in the two populations,
with greater improvements in rescue use with
UMEC/VI versus TIO. UMEC/VI reduced the risk
of short-term clinically important deterioration
versus TIO [hazard ratio; 95% confidence
interval: MN: 0.66 (0.51–0.85); ITT: 0.62
(0.54–0.71), both P B 0.001]. Adverse events
were similar across both populations and
treatments.
Conclusions: Early use of dual-bronchodilator
therapy has superior efficacy on lung function
and may reduce the risk of short-term
deterioration compared to monotherapy in
symptomatic patients with COPD.
Clinical trial registration: GSK analysis 202066
(NCT01316900/DB2113360, NCT01316913/
DB2113374, NCT01777334/ZEP117115).
Funding: This study was funded by GSK.
Keywords: Chronic obstructive pulmonary
disease; Clinically important deterioration;
Respiratory; Umeclidinium; Vilanterol
INTRODUCTION
There is evidence to suggest that early initiation
of maintenance bronchodilator therapy in
patients with chronic obstructive pulmonary
disease (COPD) may provide benefits in lung
function and health status [1–3]. A recent study
also reported that dual-bronchodilator
maintenance therapy with a long-acting
muscarinic antagonist (LAMA) plus a
long-acting b2-agonist (LABA) may provide
improvements in lung function in
treatment-naı¨ve patients and patients with less
severe COPD, as well as those already receiving
maintenance therapy [4].
Since many patients with COPD with
moderate lung function impairment remain
symptomatic with mono-bronchodilator
therapy [5], a rationale for the use of dual
bronchodilators in these patients is emerging.
The effects of early initiation of maintenance
therapy with long-acting bronchodilators are
not yet fully characterized, and fundamental
questions remain regarding the most
appropriate timing of maintenance
bronchodilator therapy initiation for COPD
and which patients would benefit most from
dual-bronchodilator treatment versus
monotherapy. To assess these points it is
important to consider not just improvements
but also the risk of deterioration in both lung
function and health status in COPD with
dual-bronchodilator versus standard LAMA
monotherapy when used as either first- or
second-line therapy.
Short-term clinically important deterioration
(CID) is a new composite endpoint in COPD,
which encompasses the occurrence of clinically
significant, recognized deteriorations (termed
minimal clinically important differences) in
lung function, quality of life (QoL), and
moderate-to-severe exacerbations that can be
used as a measure of disease worsening [6–9].
This composite endpoint is consistent with
current Global initiative for chronic
Obstructive Lung Disease (GOLD) guidelines
[10], which recommend that lung function,
health status, and COPD exacerbation risk are
considered when assessing disease progression
and severity. There are currently limited
objective means to assess symptomatic
patients at an early stage in the course of
COPD; therefore, assessment of CID may
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provide useful information on how to maintain
patient stability and prevent deterioration.
The objective of this pooled analysis was to
compare the efficacy of the LAMA/LABA
combination, umeclidinium/vilanterol (UMEC/
VI), and the widely used LAMA, tiotropium
(TIO), in a subgroup of maintenance-naı¨ve
(MN) patients relative to a larger
intent-to-treat (ITT) population, based on lung
function, health-related QoL (HRQoL), rescue
medication use, and prevention of CID in
patients with COPD and moderate-to-severe
breathlessness.
METHODS
Study Design, Treatments, and Patients
This was a post hoc analysis (GSK analysis:
202066) of data from three multicenter,
randomized, 24-week, parallel-group, blinded
trials selected because they compared UMEC/VI
and TIO: ZEP117115 (NCT01777334) [11],
DB2113374 (NCT01316913) [12], and
DB2113360 (NCT01316900) [12].
Patients were randomized to receive
once-daily inhaled UMEC/VI 62.5/25 mcg
(delivering 55 mcg and 22 mcg, respectively)
via the ELLIPTATM dry powder inhaler or TIO
18 mcg via the HandiHaler. Studies DB2113360
andDB2113374 also included treatment arms for
once-daily UMEC/VI 125/25 mcg (delivering
113 mcg and 22 mcg) and either VI 25 mcg
(DB2113360) or UMEC 125 mcg (DB2113374).
Datawere included in the analysis, but results are
not presented in this manuscript [11, 12].
Patients were aged C40 years, had a diagnosis
of symptomatic COPD [13], a modified Medical
Research Council Dyspnea Scale score C2 (i.e.,
all patients had moderate-to-severe
breathlessness), had a post-bronchodilator
forced expiratory volume in 1 s (FEV1) of
B70% predicted, and an FEV1/forced vital
capacity ratio\0.70. Patients were excluded if
they had a current diagnosis of asthma or other
known respiratory condition.
All procedures followed in the studies were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
fromall patients for being included in the studies.
Outcomes and Assessments
The primary endpoint in all studies was change
from baseline in trough FEV1 on day 169,
defined as the mean of the FEV1 values
obtained 23 and 24 h after dosing on day 168.
St George’s Respiratory Questionnaire (SGRQ)
total score was assessed in each study. SGRQ
responders were defined as patients who
experienced a decrease from baseline of C4
units [6]. Daily use of rescue medication was
also assessed. As a minimal clinically important
difference for rescue medication use is not yet
defined, we pre-specified a treatment benefit of
1 rescue-free month per year or 2 rescue-free
weeks out of 24 (corresponding to a change
from baseline C8.3% in the percentage of
rescue-free days over weeks 1–24) as clinically
important and used this value as the definition
of rescue medication responders.
This analysis was performed on a subgroup
of MN patients (defined as receiving no
maintenance therapy for C30 days before
screening) and the ITT population and
assessed the time to, and risk of, a short-term
CID. CID was defined as: a decrease from
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baseline of C100 ml in trough FEV1 [9], and/or
an increase from baseline of C4 units in SGRQ
total score [6], and/or an on-treatment
moderate-to-severe COPD exacerbation
(defined as a worsening of COPD symptoms
requiring use of any additional treatment other
than study drug or rescue albuterol use and an
emergency department visit or hospitalization).
Deteriorations in trough FEV1 were assessed
based on data from seven trial visits
post-randomization (days 2, 28, 56, 84, 112,
168, and 169) and SGRQ from three study visits
(days 28, 84, and 168).
Sustained CIDs were also assessed and
defined as: a moderate-to-severe COPD
exacerbation leading to study withdrawal, or
an FEV1 decrease C100 ml or an SGRQ total
score increase C4 units from baseline on two
consecutive visits, or for C50% of all available
subsequent visits. As the protocols from the
studies mandated that patients be withdrawn
from the study following a moderate-to-severe
COPD exacerbation, the first incidence of a
moderate-to-severe COPD exacerbation was also
considered a component of sustained CID. In
each study, adverse events (AEs) were
monitored.
Statistical Analysis
Statistical comparisons were presented for
UMEC/VI 62.5/25 mcg versus TIO. Trough
FEV1 and SGRQ comparisons were analyzed
using a repeated measures model including
covariates of study, treatment, baseline score,
smoking status, geographical region, day, day
by baseline, and day by treatment. Comparisons
of rescue-free days were analyzed using logistic
regression with covariates of study, treatment,
baseline percentage, smoking status, and
geographical region. Comparisons of the time
to a first or sustained short-term CID, and each
individual component within these endpoints,
were analyzed using a Cox proportional hazards
model including covariates of study, treatment,
smoking status at screening, and geographical
region.
Compliance with Ethics Guidelines
All procedures followed in the studies were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained




The ITT population in the UMEC/VI 62.5/25
and TIO group consisted of 1747 patients, of
which 533 patients formed the MN subgroup of
interest. The other treatment arms (UMEC
125.25, VI 25, and UMEC 125) comprised 850
patients in total but were not included in the
analysis as they are unlicensed medications and
doses. Although certain patient demographics
such as age, sex, and reversibility were similar in
the ITT and MN populations, there were some
notable differences (Table 1). More patients in
the MN subgroup were current smokers than in
the ITT population (65% vs. 52% in patients
treated with UMEC/VI and 60% vs. 51% in
patients treated with TIO). As expected, more
patients in the MN subgroup had moderate
COPD (GOLD stage II) than severe/very
severe COPD (GOLD stage III/IV), and
post-albuterol % predicted FEV1 was higher in
the MN population.
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Efficacy
Trough FEV1: In both the MN and ITT
populations, UMEC/VI was associated with
statistically significant improvements
compared with TIO in trough FEV1 from day
2. At day 169 mean improvements in trough
FEV1 from baseline were significantly greater for
UMEC/VI versus TIO in both populations’ least
squares (LS) mean difference [95% confidence
interval (CI)]: MN population: 146 ml
(102–189); P\0.001; ITT population: 95 ml
(71–118), P\0.001 (Fig. 1).
Health-related quality of life: UMEC/VI and
TIO provided mean improvements (C4-unit
decrease) from baseline in total SGRQ score, in
Table 1 Patient demographics and baseline characteristics











Age, years, mean (SD) 63.0 (8.6) 63.4 (8.7) 61.7 (8.6) 62.3 (8.7)
Male, n (%) 596 (68) 594 (68) 194 (71) 165 (64)
Current smoker at screeninga, n (%) 457 (52) 439 (51) 180 (65) 155 (60)
Smoking pack-yearsb, n (%) 45.1 (25.6) 46.1 (27.0) 47.1 (25.6) 49.5 (30.1)
Reversible to albuterolc,d, n (%) 243 (28) 248 (29) 94 (34) 77 (30)
Post-albuterol% predicted FEV1 Mean (SD)
e 47.0 (13.1) 47.0 (12.99) 50.9 (12.27) 50.1 (12.84)
GOLD stage, nf* (%)
II 393 (45) 385 (44) 154 (56) 141 (55)
III 372 (42) 375 (43) 103 (38) 94 (37)
IV 111 (13) 106 (12) 17 (6) 22 (9)
ICS use at screeningg, n (%)
Yes 443 (50) 445 (51) 0 0
Exacerbation historyh, n (%)
Required corticosteroid and/or antibiotic
(without hospitalization)
193 (22) 215 (25) 57 (21) 45 (17)
Required hospitalization 73 (8) 80 (9) 18 (7) 20 (7)
FEV1 forced expiratory volume in 1 s, GOLD global initiative for chronic obstructive lung disease, ICS inhaled
corticosteroid, ITT intent to treat, MN maintenance-naı¨ve, SD standard deviation, TIO tiotropium, UMEC umeclidinium,
VI vilanterol
a Patient reclassiﬁed as current smoker if smoked within 6 months
b Smoking pack-years = (number of cigarettes smoked per day/20) 9 number of years smoked
c Reversibility was deﬁned as an increase in FEV1 of C12% and C200 ml following administration of albuterol
d ITT population: UMEC/VI, n = 876; TIO, n = 863
e ITT population: UMEC/VI, n = 876; TIO, n = 866, MN population: UMEC/VI, n = 274; TIO n = 257
f UMEC/VI, n = 873; TIO, n = 859
g ICS use was deﬁned as those patients who were currently taking ICS medications at the screening visit
h Patients experiencing C1 exacerbation during the 12 months prior to screening
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both the MN and ITT populations, throughout
the study (Fig. 2). Improvements versus
baseline were numerically greater in the MN
population compared with the ITT population
for both treatment regimens at all visits. SGRQ
total scores were significantly improved with
UMEC/VI versus TIO in the ITT population on
day 28 (-2.25 units, 95% CI: -3.26 to -1.23;
P\0.001) and day 84 (-1.63: 95% CI: -2.76 to
-0.49; P = 0.005), but not on day 168 (-0.93;
95% CI: -2.19 to 0.33; P = 0.149) (Fig. 2). In
the smaller MN population, the SGRQ
treatment differences were in favor of UMEC/
VI at all time points, but were not significant
(Fig. 2).
The odds of being an SGRQ responder
(C4-unit decrease) versus a non-responder was
significantly greater with UMEC/VI treatment
compared with TIO treatment at days 28 and 84
in the ITT population (OR: 1.3 at both time
points; P = 0.007 day 28; P = 0.009 day 84), but
was not significantly different in the MN
population (Table S1). At day 168, the odds of
being a responder versus a non-responder were
not significantly different between treatment
groups in either the MN or ITT populations
(Table S1).
Rescue medication use: The percentage of
patients achieving a response in rescue-free
episodes was significantly greater with UMEC/
VI compared with TIO in both the ITT [46% vs.
36%; OR: 1.5 (95% CI: 1.2–1.9)] and MN [47%
vs. 37%; OR: 1.5 (95% CI: 1.0–2.2)] populations
(Table 2). The mean number of puffs/day over
weeks 1–24 was improved for UMEC/VI versus
TIO in both the ITT and MN populations
[difference (ITT): -0.5 (95% CI: -0.8 to -0.3)
puffs/day; P\0.001; (MN): -0.5 (95% CI: -0.9
to 0.0); P = 0.066].
The proportion of patients with a short-term
composite CID was lower with UMEC/VI
treatment versus TIO treatment in both
populations (MN population: 41% vs. 55%;
ITT population: 41% vs. 56%). The risk of a
first CID was reduced with UMEC/VI compared
with TIO in the MN population [HR = 0.66
(0.51–0.85); P = 0.001] (Fig. 3). Similar results
were observed for UMEC/VI treatment versus
TIO in the ITT population [HR (95% CI) = 0.62
(0.54 to 0.71); P\0.001] (Fig. 3).
When the individual components of a first
short-term CID were assessed, a significant
reduction in the risk of deterioration in lung
function was observed for UMEC/VI treatment
versus TIO in both the MN and ITT
Fig. 1 Trough FEV1 changes over time in the ITT and
MN populations. CI conﬁdence interval, FEV1 forced
expiratory volume in 1 s, ITT intent to treat, LS least
squares, MN maintenance-naı¨ve, TIO tiotropium, UMEC
umeclidinium, VI vilanterol
Fig. 2 SGRQ total score mean change from baseline in
the ITT and MN populations. CI conﬁdence interval, ITT
intent to treat, LS least squares, MCID minimal clinically
important difference, MN maintenance-naı¨ve, SGRQ St
George’s respiratory questionnaire, TIO tiotropium,
UMEC umeclidinium, VI vilanterol
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populations (Table 3). The risk of a CID on
SGRQ total score was also significantly
reduced with UMEC/VI treatment compared
with TIO, but only in the ITT population
(Table 3). There was no significant difference
between the treatment groups in the risk of a
moderate-to-severe exacerbation in either
population.
Table 2 Summary and analysis of rescue medication use
Rescue use, puffs/day, weeks 1–24 UMEC/VI TIO
ITT population, n 776 764
LS mean change from baseline (SE) -2.0 (0.09) -1.40 (0.10)
UMEC/VI vs. TIO, OR (95% CI) -0.5 (-0.8 to -0.3)*
MN population, n 241 225
LS mean change from baseline (SE) -1.6 (0.18) -1.1 (0.18)
UMEC/VI vs. TIO, OR (95% CI) -0.5 (-0.9 to 0.0)
Rescue-free episodes
ITT population, n 776 764
Patients achieving increasea, n(%) 357 (46) 273 (36)
UMEC/VI vs. TIO, OR (95% CI) 1.5 (1.2 to 1.9)*
MN population, n 241 225
Patients achieving increase, n(%) 114 (47) 84 (37)
UMEC/VI vs. TIO, OR (95% CI) 1.5 (1.0 to 2.2)§
CI conﬁdence interval, ITT intent to treat, LS least squares, MN maintenance-naı¨ve, OR odds ratio, TIO tiotropium,
UMEC umeclidinium, VI vilanterol
* P\0.001,  P\0.01; § P\0.05,  P = 0.066 for UMEC/VI vs. TIO
 n is the number of patients with analyzable data at the current time point
a Patients demonstrating a treatment effect similar to 1 extra rescue-free month per year or 2 extra rescue-free weeks in 24 (a
change from baseline C8.3% over weeks 1–24)
Fig. 3 Time to ﬁrst CID in the a ITT and b MN populations. CID clinically important deterioration, ITT intent to treat,
MN maintenance-naı¨ve, TIO tiotropium, UMEC umeclidinium, VI vilanterol, HR hazard ratio, CI conﬁdence interval
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Risk of sustained CID: The proportion of
patients with a sustained CID was
approximately half of that observed for the
first CID and was lower for UMEC/VI versus TIO
in both the MN population (22% vs. 30%) and
the ITT population (21% vs. 30%). The risk of a
sustained CID was significantly reduced in the
UMEC/VI treatment group versus the TIO
treatment group, for both the MN and ITT
populations [MN population: HR = 0.69 (0.49
to 0.97); P\0.05]; ITT population: HR = 0.64
(0.53 to 0.77), P\0.001; (Table S2)].
Safety: Overall, the incidences of AEs were
similar for the two treatment groups in both the
ITT and MN populations, with nasopharyngitis
and headache reported most frequently. One
exception was a lower incidence of upper
respiratory tract infection in the UMEC/VI
treatment group compared with TIO in the
MN population [2 vs. 10 patients (\1% vs. 4%)].
The incidences of non-fatal serious AEs and fatal
AEs were also similar between both populations
(Table 4). Pneumonia and cardiovascular events
occurred in \1% in the UMEC/VI and TIO
groups (in both populations).
DISCUSSION
This is the first analysis to compare the
differences between UMEC/VI and TIO in a
MN COPD population, looking at indices of
both improvement and deterioration including
the novel composite endpoint of short-term
CID, which encompasses multiple elements and
measurement of short-term worsening in COPD
advocated in current guidelines.
In this analysis, UMEC/VI provided
improvements in trough FEV1 from baseline
compared with TIO in both the MN and ITT
populations, with the largest magnitude of
effect seen in MN patients. The greater
treatment effect on trough FEV1 in the MN
population could, in part, be related to reduced
confounding because of background ICS
therapy, but may also be due to patients with
less impaired lung function having greater
Table 3 Summary and analysis of ﬁrst deterioration events in the ITT and MN populations
Components of the ﬁrst CID UMEC/VI 62.5/25 TIO Hazard ratio, UMEC/VI
vs. TIO
(95% CI)
ITT population, n 878 869
C100 ml decrease in trough FEV1 159 (18) 308 (35) 0.44 (0.36 to 0.53)*
C4-unit SGRQ total score increase 208 (24) 236 (27) 0.83 (0.69 to 1.00)
Moderate-to-severe COPD exacerbation 56 (6) 54 (6) 1.02 (0.70 to 1.48)
MN population, n 275 258
C100 ml decrease in trough FEV1 53 (19) 93 (36) 0.44 (0.32 to 0.62)*
C4-unit SGRQ total score increase 66 (24) 69 (27) 0.92 (0.65 to 1.29)
Moderate-to-severe COPD exacerbation 13 (5) 9 (3) 1.33 (0.57 to 3.13)
Data presented as n (%) unless otherwise indicated
CI conﬁdence interval, CID clinically important deterioration, COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, ITT intent to treat, MN maintenance-naı¨ve, SGRQ St George’s respiratory questionnaire, TIO
tiotropium, UMEC umeclidinium, VI vilanterol
* P\0.001,  P\0.05
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capacity to benefit from increased
bronchodilator therapy [14]. Consistent with
this, a recent study assessing the efficacy of TIO
plus olodaterol versus TIO monotherapy also
demonstrated improvements from baseline in
trough FEV1 that tended to be greater in
patients with less severe COPD and who were
LAMA or LABA naı¨ve [4].
This study also assessed the effect of UMEC/
VI and TIO treatment on the composite
endpoint of short-term CID, which is designed
to address clinically important early signs of
deterioration in lung function, health status,
and/or COPD exacerbations. A recent study has
demonstrated the dual bronchodilator therapy
may reduce the risk of short-term CID and
potentially provide greater airway stability
compared with monotherapy [15].
One additional potential advantage of the
CID approach is that it provides a means to
assess symptomatic patients, including MN
patients at risk of deterioration at an early
stage in the course of COPD, potentially
providing useful information on how to
prevent deterioration and maintain stability or
when to escalate therapy.
This analysis demonstrated that UMEC/VI
reduced the risk of a first composite short-term
CID compared with TIO to a similar extent in
both the ITT and MN populations. These
Table 4 Summary of AEs









AEs reported by C3% of patients on any treatment, n(%)
Nasopharyngitis 63 (7) 62 (7) 18 (7) 15 (6)
Headache 80 (9) 55 (6) 20 (7) 15 (6)
Back pain 27 (3) 28 (3) 8 (3) 4 (2)
Cough 25 (3) 26 (3) 5 (2) 8 (3)
Upper respiratory tract infection 17 (2) 26 (3) 2 (\1) 10 (4)
AEs of special interest
Cardiovascular events (any) 2 (\1) 2 (\1) 0 1 (\1)
Pneumonia 2 (\1) 6 (\1) 0 1 (\1)
On-treatment non-fatal SAEs
Any event, n(%) 42 (5) 35 (4) 8 (3) 11 (4)
Fatal AEsa
Any event, n(%) 4 (\1) 7 (\1) 3 (1) 2 (\1)
AE adverse event, COPD chronic obstructive pulmonary disease, ITT intent to treat, MN maintenance-naı¨ve, SAE serious
adverse event, TIO tiotropium, UMEC umeclidinium, VI vilanterol
a Deaths were attributable to the following: ITT: cardiac arrest, cardiac failure, COPD, and hemorrhagic stroke in the
UMEC/VI group; cardiac failure, pulmonary embolism, respiratory arrest, respiratory failure, upper gastrointestinal
hemorrhage, sudden death, and pancreatic carcinoma in the TIO group. MN: Cardiac arrest, hemorrhagic stroke, and
COPD in the UMEC/VI group; respiratory arrest and respiratory failure in the TIO group
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preliminary results in MN patients provide
additional insight into the potential benefits
of optimizing lung function in low-risk
symptomatic patients with COPD. The
improved bronchoprotection seen with dual
bronchodilators versus monotherapy in both
the MN and ITT cohorts in this analysis may be
indicative of more prolonged disease stability.
Further, validation of this endpoint is ongoing
to better understand the long-term
consequences of short-term CID on morbidity
and mortality over several years of follow-up
[16].
Previous studies have demonstrated an
accelerated lung function decline in patients
with moderate compared with severe and very
severe COPD; therefore, optimizing
bronchodilator treatment at an earlier stage
may provide longer term benefits [1, 2, 17]. In
support of this, early maintenance treatment
with TIO was shown to be associated with
long-term sustained benefits in the 4-year
UPLIFT study, with a slower decline in lung
function and HRQoL [3, 18]. In a previous
publication, which examined time to a first CID
with UMEC/VI versus TIO and placebo in both
GOLD B and D subgroups, no apparent
differences were found in the magnitude of
treatment benefit on the incidence of CID based
on levels of lung function impairment or
disease severity at baseline [15]. The current
study focused on patients from three similar
studies with a large proportion of symptomatic
COPD patients (all mMRC C2), 55% and 45% of
the ITT and MN subgroups, respectively,
presenting with severe lung function
impairment at baseline. The current findings
are commensurate with the earlier study by
Singh and colleagues [15], highlighting that
reducing the risk of a first CID is as likely in low
and high risk patients and when using dual
bronchodilators as first- or second-line therapy.
It is therefore important that the early use of
dual therapy was compared with monotherapy
in this MN population.
Safety data were similar for both the MN and
ITT populations when comparing UMEC/VI and
TIO. A low number of serious AEs [including
few cardiac events and incidences of
pneumonia (B2% in any treatment group)]
and a low mortality rate (B1%) were reported
with each treatment in each population. As
such, the data present no increased safety
concern for the earlier use of UMEC/VI
compared with LAMA monotherapy in the
course of COPD treatment. This is also
supported by the results of a recent network
meta-analysis that demonstrated no increased
safety signal for LAMA/LABAs versus either
mono LAMAs or LABAs [19].
One key limitation of the study is the
retrospective nature of the findings.
Additionally, only patients with
moderate-to-severe breathlessness were
included in the original clinical studies
comparing UMEC/VI and TIO, and all
patients had a low exacerbation risk.
Consequently, it is possible that patients
who are less symptomatic than those studied
here could be managed on monotherapy.
Also, exacerbations as a deterioration
parameter had limited potential to feature
strongly in this short-term analysis. Therefore,
a longer follow-up may mean that
exacerbations feature more prominently in
the CID endpoint in low-risk patients
receiving bronchodilators without concurrent
ICS. Whilst the occurrence of short-term CID
has been linked with long-term poor
outcomes, further validation of the CID
endpoint in prospective trials of increased
duration are needed to better understand
long-term outcomes in COPD with dual-
versus mono-bronchodilator therapy.
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CONCLUSIONS
The efficacy and safety data presented here
support the use of dual-bronchodilator therapy
as the first-line maintenance treatment option
in patients with moderate-to-severe
breathlessness and a low risk of exacerbations.
The impact of dual- versus
mono-bronchodilator therapy on the natural
history of COPD requires validation with
long-term prospective studies.
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